Inclusion Criteria:

- Patients must have histologically-confirmed malignancy

- Patients must have recurrent or metastatic tumor located within a previously
irradiated field

- Tumor within the irradiated field is negatively impacting patient's quality of life
or threatening catastrophic complication if left untreated as determined by the
treating physician

- Patient is not a candidate for, or has not demonstrated a significant local response
to chemotherapy, biologic, hormonal ,or other therapies

- Patient is not a surgical candidate or tumor is not surgically resectable, as
documented by surgical oncologist

- Information on previous radiation treatment, including total dose and fractionation
must be available; additional information including radiation fields and
dose-volume-histogram or isodose lines is preferable

- Tumor sites eligible for inclusion on this protocol include thorax, abdomen, and
pelvis

- Patients must have measurable disease per Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 in the previously irradiated field

- Women of childbearing potential must be non-pregnant (negative pregnancy test within
72 hours prior to radiation simulation, postmenopausal woman must have been
amenorrheic for at least 12 months to be considered of non-childbearing potential)
and nonlactating, and men and women must be willing to exercise an effective form of
birth control (abstinence/contraception) while on study and for 3 months after
therapy completed

- Eastern Cooperative Oncology Group (ECOG) performance status determined to be between
0 and 3

- Absolute neutrophil count (ANC) >= 1,500/ul

- Platelets (PLT) >= 75,000/ul

- Subjects must sign a written informed consent and Health Insurance Portability and
Accountability Act (HIPAA) consent prior to performance of study-specific procedures
or assessments and must be willing to comply with treatment and follow-up

Exclusion Criteria

- Patients who have had chemotherapy or radiotherapy to the reirradiation target within
4 weeks prior to entering the study

- Concurrent chemotherapy or biologic therapy

- A history of ataxia telangiectasia or other documented history of radiation
hypersensitivity

- Scleroderma or active connective tissue disease

- For abdominal or pelvic irradiation: active inflammatory bowel disease

- Serious, active infections requiring treatment with intravenous (IV) antibiotics

- Uncontrolled intercurrent illness including, but not limited to, or psychiatric
illness/social situations that would limit compliance with study requirements

- Reirradiation targets located within the head, neck, or brain are excluded from this
study